Background and Need for Real-World Data Analysis

Jardiance (empagliflozin), an SGLT2 inhibitor, has expanded its therapeutic scope beyond diabetes and heart failure to include chronic kidney disease (CKD). Recent research suggests that SGLT2 inhibitors may positively impact renal anemia, a major cause of mortality and reduced quality of life in CKD patients. Consequently, Boehringer Ingelheim and Eli Lilly have launched a large-scale clinical study (NCT07063316) utilizing real-world data (RWD) from Japanese patients. This study aims to rigorously validate the efficacy of Jardiance in alleviating renal anemia and reducing the use of other treatments in a real-world clinical setting.

Study Design with Precise Matching

This observational study involves approximately 15,000 patients registered in the Medical Data Vision (MDV) database in Japan. To minimize bias in patient matching, the research team employs a nested case-control design and incidence density sampling. This approach enables a precise analysis of the Jardiance-treated group and a control group, tracking the incidence of renal anemia. Patient enrollment began in July 2025, with data collection scheduled for completion by December 2026.

Tracking the Use of Anemia Medications and Healthcare Costs

The primary analysis focuses not only on changes in blood test results but also on the prescription patterns and dosage reductions of existing anemia treatments, such as erythropoiesis-stimulating agents (ESAs) and hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PH inhibitors). Furthermore, the study compares the actual reduction in healthcare costs associated with renal anemia resulting from these treatment pattern changes. Researchers anticipate that Jardiance will reduce reliance on existing medications by stimulating the production of erythropoietin (EPO) and improving iron metabolism. This is expected to improve patient compliance and provide direct evidence to alleviate the growing financial burden of chronic diseases on national healthcare systems.

Impact on the Pharmaceutical and Healthcare Markets

If Jardiance's efficacy in improving renal anemia is demonstrated through RWD, it will provide a strong competitive advantage against other drugs, such as Forxiga (dapagliflozin) from AstraZeneca, in terms of market share. The global market for renal anemia treatments is currently estimated at approximately USD 7.8 billion, with intense competition from new drugs like Evrenzo from Astellas. If Jardiance provides additional clinical benefits for patients with chronic kidney disease and anemia, its portfolio value will undoubtedly be maximized. This study is expected to have a significant impact not only on the aging Japanese market but also on the future revision of global guidelines for the treatment of kidney diseases.